

Title: The impact of co-morbidity in childhood Cystic Fibrosis

Authors: Julie A. Duncan, Sarah M.N. Brown

PII: S1526-0542(17)30032-5
DOI: http://dx.doi.org/doi:10.1016/j.prrv.2017.03.009
Reference: YPRRV 1207

To appear in: *YPRRV*

Please cite this article as: Duncan Julie A, Brown Sarah M.N.The impact of co-morbidity in childhood Cystic Fibrosis.*Paediatric Respiratory Reviews* http://dx.doi.org/10.1016/j.prrv.2017.03.009

The impact of co-morbidity in childhood Cystic Fibrosis

Julie A. Duncan[1*] julieduncan@doctors.org.uk, Sarah M. N. Brown[1]

[1]The Royal London Hospital, Barts Health NHS Trust, London, UK

*Corresponding author.

Summary

A number of risk factors have been identified for deterioration of lung disease in children with Cystic Fibrosis (CF), and current management strategies are based on the prevention and treatment of such elements. Further challenge ensues when a patient has co-morbid disease in addition to CF, particularly when faced with rapidly deteriorating pulmonary status. It is difficult to measure the contribution of other pathologies to this decline and optimisation of both CF care and co-morbidity is paramount. This review explores the challenges faced when treating children with CF and co-morbid conditions, focussing on gastroesophageal reflux disease pre- and post-lung transplantation.

Keywords: Cystic Fibrosis; Gastroesophageal reflux disease; Paediatric Lung Transplantation; Co-morbid disease